JP2021531312A5 - - Google Patents

Info

Publication number
JP2021531312A5
JP2021531312A5 JP2021504238A JP2021504238A JP2021531312A5 JP 2021531312 A5 JP2021531312 A5 JP 2021531312A5 JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021504238 A JP2021504238 A JP 2021504238A JP 2021531312 A5 JP2021531312 A5 JP 2021531312A5
Authority
JP
Japan
Prior art keywords
influenza
conjugate
influenza virus
agent
agent according
Prior art date
Application number
JP2021504238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531312A (ja
JPWO2020023323A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042715 external-priority patent/WO2020023323A1/en
Publication of JP2021531312A publication Critical patent/JP2021531312A/ja
Publication of JPWO2020023323A5 publication Critical patent/JPWO2020023323A5/ja
Publication of JP2021531312A5 publication Critical patent/JP2021531312A5/ja
Priority to JP2023212681A priority Critical patent/JP2024029005A/ja
Pending legal-status Critical Current

Links

JP2021504238A 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体 Pending JP2021531312A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212681A JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862703534P 2018-07-26 2018-07-26
US62/703,534 2018-07-26
US201962846549P 2019-05-10 2019-05-10
US62/846,549 2019-05-10
PCT/US2019/042715 WO2020023323A1 (en) 2018-07-26 2019-07-20 Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212681A Division JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Publications (3)

Publication Number Publication Date
JP2021531312A JP2021531312A (ja) 2021-11-18
JPWO2020023323A5 JPWO2020023323A5 (https=) 2022-07-26
JP2021531312A5 true JP2021531312A5 (https=) 2022-07-26

Family

ID=69180703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504238A Pending JP2021531312A (ja) 2018-07-26 2019-07-20 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212681A Pending JP2024029005A (ja) 2018-07-26 2023-12-18 抗インフルエンザ化学療法および免疫療法のための低分子リガンド標的指向性薬物結合体

Country Status (7)

Country Link
US (1) US20210393786A1 (https=)
EP (1) EP3826681A4 (https=)
JP (2) JP2021531312A (https=)
CN (1) CN112672762B (https=)
AU (1) AU2019312144B2 (https=)
CA (1) CA3107778A1 (https=)
WO (1) WO2020023323A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
EP4175637A4 (en) * 2020-07-02 2024-08-07 Purdue Research Foundation Tetrahydro-3h-pyrazolo quinolone and tetrahydro-3h-pyrrolo[3,2-f]quinoline-containing compounds and uses thereof
WO2022015754A2 (en) * 2020-07-13 2022-01-20 University Of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
EP4337663A4 (en) * 2021-05-14 2026-04-15 Purdue Research Foundation BISPECIFIC SMALL MOLECULE-BASED IMMUNE CELL ATTACHMENTS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION
MX2024000897A (es) * 2021-07-28 2024-02-06 Regeneron Pharma Conjugados de proteina y compuestos antivirales.
CN119403574A (zh) * 2022-04-19 2025-02-07 普渡研究基金会 双半抗原和三半抗原缀合物、组合物、制备方法及其治疗方法
CN116375647A (zh) * 2023-01-21 2023-07-04 兰州大学 一种基于Click反应的CAR-T细胞药物递送平台及其构建方法与应用
WO2025085664A1 (en) * 2023-10-17 2025-04-24 Mary Lynn Niedrauer Conjugates, com positions and methods for treating influenza
WO2025133395A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Bicyclic (hetero)arylene wrn inhibitory compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
ES2518926T3 (es) * 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
WO2002028411A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
CN102036658A (zh) * 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CN103068378B (zh) * 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
US9250238B2 (en) * 2010-06-25 2016-02-02 Purdue Research Foundation Pathogen detection
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10975112B2 (en) * 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
JP7282521B2 (ja) * 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物

Similar Documents

Publication Publication Date Title
JP2021531312A5 (https=)
JP4868698B2 (ja) マクロファージが仲介する疾患の治療および診断
Davies et al. In vivo and in vitro effects of tumour specific antibodies with chlorambucil
JP2025024041A5 (https=)
JPWO2020023323A5 (https=)
JP2017507931A5 (https=)
JP2020002172A5 (https=)
KR970706018A (ko) 백신 조성물(vaccine compositions)
HRP20171580T1 (hr) Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba
WO2007134037A3 (en) Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
AU2015258801B2 (en) One-step labeling of antibodies to high specific activity with actinium-225
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
JP2013534528A (ja) 脂質とコンジュゲートする抗体
Jagadeesh et al. Antibody drug conjugates (ADCs): changing the treatment landscape of lymphoma
KR20200006546A (ko) 항-folr1 면역접합체 및 항-pd-1 항체 조합물
WO2022040429A3 (en) Vaccine compositions and antibodies for lyme disease
JP2006511620A5 (https=)
Sharkey et al. Biological considerations for radioimmunotherapy
JP2021501800A5 (https=)
JP2015529656A5 (https=)
US9289519B2 (en) Alpha emitting constructs and uses thereof
JP2010529950A5 (https=)
JPS61197528A (ja) 免疫毒素製剤
Scheinberg Current applications of monoclonal antibodies for the therapy of hematopoietic cancers
CA2333125C (en) Alpha emitting constructs and uses thereof